The regulatory agencies in the most highly regulated venues commonly request information on the safety and effectiveness of study drugs in a real world setting, requiring pharma companies to expand the reach of current research efforts into postmarketing programs. Cromos Pharma is one of the few clinical research professional organizations with advanced experience in the implementation of these studies together with a keen focus on successfully meeting market challenges and addressing FDA/EMEA safety commitments.

Cromos Pharma is active in the following fields:

  • Post-approval patient registries
  • Phase IV Clinical Trials
  • Non-interventional (observational) programs

We have successfully managed post-marketing studies ranging in size across all major therapeutic areas including oncology, cardiovascular, ophthalmology, dermatology, surgery, endocrinology, urology, gastroenterology and infectious diseases. The largest project that Cromos Pharma has run was a multinational observational study in the area of cardiology with a target site number of 1,200 sites and with a patient recruitment target of 12,000 participants.

Our intuitive EDC system with ePRO software, accessed by patients via their smartphones, optimizes research investments by efficiently streamlining the clinical trial process. Toll free numbers provide a supportive and accessible resource for doctors participating in postmarketing programs.

If you are interested in our post-marketing services, please contact our Business Development team.